| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 14th October 2020 | Bryan Giraudo | 3,000 | Open or private purchase | $10.01 | $30,036.00 |
| 11th August 2020 | Chaitan Phd Khosla | 2,499 | Open or private sale | $17.19 | $42,952.06 |
| 11th August 2020 | Chaitan Phd Khosla | 2,499 | Exercise of derivative | $1.89 | $4,723.11 |
| 23rd June 2020 | Bryan Giraudo | 2,000 | Open or private purchase | $12.96 | $25,922.40 |
| 29th April 2020 | Dinesh V Ph D Patel | 2,000 | Bona fide gift | $0.00 | |
| 20th March 2020 | Dinesh V Ph D Patel | 10,000 | Exercise of derivative | $1.89 | $18,900.00 |
| 12th March 2020 | Dinesh V Ph D Patel | 18,344 | Exercise of derivative | $1.16 | $21,279.04 |
| 12th March 2020 | Harold E Selick | 12,000 | Open or private purchase | $6.70 | $80,400.00 |
| 14th February 2020 | Bryan Giraudo | 46,500 | Grant/award etc. | $0.00 | |
| 3rd December 2019 | Dinesh V Ph D Patel | 10,000 | Open or private purchase | $5.55 | $55,500.00 |
Protagonist Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm's initial lead product candidates are being developed for moderate-to-severe ulcerative colitis and Crohn's disease.
Ticker: PTGX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1377121
Employees: 64
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $300 Th for the period May 2020 to May 2020 in the context of all up
Fundamentals
Cash at Carrying Value: $146 M (0%)
Marketable Securities, Current: $62 M (0%)
Assets, Current: $217 M (49%)
Property, Plant and Equipment, Net: $2 M (-7%)
Assets: $225 M (45%)
Accounts Payable, Current: $3 M (2%)
Accrued Liabilities, Current: $13 M (4%)
Liabilities, Current: $35 M (0%)
Liabilities: $57 M (-23%)
Common Stock, Shares, Issued: $37 M (35%)
Additional Paid in Capital, Common Stock: $425 M (42%)
Retained Earnings (Accumulated Deficit): $257 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $208 Th (-5%)
Stockholders' Equity (Parent): $167 M (0%)
Liabilities and Equity: $225 M (45%)
Research and Development: $20 M (-48%)
General and Administrative Expenses: $4 M (-52%)
Operating Income/Loss: $18 M (-51%)
Provision for income taxes: $1 M (2%)
News
Healthcare Improves While Biotechs Look Great
1st December 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
